TransMedics: A Look At What Is Behind The Loss Of Sales Momentum In H2 2024

Group 1 - TransMedics (NASDAQ: TMDX) shares have decreased by 60% from their peak in August [2] - The stock experienced a decline prior to the Q3 earnings report and fell further after missing revenue estimates for Q3 [2] - The company has maintained its full-year revenue guidance despite the earnings miss [2] Group 2 - The article emphasizes the importance of tracking portfolio and watchlist stocks closely for potential investment opportunities [1] - The Growth Stock Forum offers a model portfolio of 15-20 stocks and a top picks list of up to 10 stocks expected to perform well [1]